Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients

乳腺癌 医学 肿瘤科 内科学 BRCA突变 三阴性乳腺癌 危险系数 癌症 外科肿瘤学 种系突变 突变 置信区间 生物 遗传学 基因
作者
Po‐Han Lin,Shin‐Cheh Chen,Ling‐Ming Tseng,King‐Jen Chang,Ai-Chu Huang,Kuo‐Chih Cheng,Karen Yang,Hui‐Chen Wu,Tsu‐Yi Chao,Yuan‐Ching Chang,Peng‐Chan Lin,Wen‐Hung Kuo,Wen-Lin Kuo,Ching‐Hung Lin,Huo-Mu Chen,Dah‐Cherng Yeh,Liang‐Chih Liu,Chun‐Yu Liu,Mingyang Wang,Chiao Lo
出处
期刊:Breast Cancer Research and Treatment [Springer Nature]
卷期号:192 (3): 629-637 被引量:7
标识
DOI:10.1007/s10549-021-06446-7
摘要

Breast cancer is increasing around the globe, including Asia. We aimed to examine the survival and risk of contralateral breast cancer (CBC) in Asian breast cancer patients with BRCA mutations.A total of 128 breast cancer patients with germline BRCA mutations and 4,754 control breast cancer patients were enrolled. Data on clinical-pathologic characteristics, survival, and CBC were collected from the medical record. The rates of survival and CBC were estimated by Kaplan-Meier method.The mean age of onset in BRCA mutation carriers was significantly younger than control patients (BRCA vs. Non-BRCA: 43.9 vs. 53.2 years old). BRCA mutation carriers had a higher proportion of triple-negative breast cancer (TNBC) (52%) than control patients (12%, p < 0.001). The risk of CBC was significantly higher in BRCA mutation patients than in control cases (hazard ratio (HR) = 3.95, 95% CI 2.71-5.75); when stratified by genotype, the HRs (95%CI) were 4.84 (3.00-7.82) for BRCA1 and 3.13 (1.78-5.49) for BRCA2 carriers, respectively. Moreover, BRCA1 mutation patients with triple-negative breast cancer (TNBC) as their first breast cancer had the highest risk of CBC (HR = 5.55, 95% CI 3.29-9.34). However, we did not observe any differences in relapse-free survival and overall survival between mutation carriers and control patients.Our study suggest that BRCA patients had a significantly higher risk of developing CBC, particularly for BRCA1 mutation carriers with TNBC as the first breast cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
将个烂就完成签到,获得积分10
1秒前
整齐百褶裙完成签到 ,获得积分10
1秒前
赘婿应助友好太兰采纳,获得10
3秒前
科研通AI2S应助drtianyunhong采纳,获得10
4秒前
炙热的宛完成签到,获得积分10
4秒前
轮子发布了新的文献求助10
4秒前
123123完成签到,获得积分10
5秒前
刘艺涵完成签到 ,获得积分10
6秒前
10秒前
11秒前
xxxx完成签到,获得积分10
11秒前
MRIFFF完成签到,获得积分10
11秒前
yziy完成签到 ,获得积分10
12秒前
鹿邑完成签到 ,获得积分10
13秒前
14秒前
深情惜梦发布了新的文献求助10
14秒前
不语君子意完成签到,获得积分10
14秒前
15秒前
33完成签到,获得积分10
16秒前
惔惔惔完成签到,获得积分10
16秒前
科研小秦完成签到,获得积分10
16秒前
16秒前
XpenG发布了新的文献求助10
16秒前
呆梨医生发布了新的文献求助10
18秒前
19秒前
shaokaizhao完成签到,获得积分10
20秒前
Orange应助fash采纳,获得10
20秒前
20秒前
KKXX51129完成签到,获得积分10
21秒前
回来完成签到,获得积分10
21秒前
22秒前
111完成签到,获得积分10
22秒前
貔貅完成签到,获得积分10
22秒前
cgs完成签到,获得积分10
22秒前
笑哈哈完成签到,获得积分10
23秒前
DD发布了新的文献求助10
23秒前
星先生完成签到 ,获得积分10
24秒前
Ava应助三木采纳,获得10
24秒前
zhuxf完成签到 ,获得积分10
24秒前
离研通完成签到,获得积分10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Modern Epidemiology, Fourth Edition 5000
Handbook of pharmaceutical excipients, Ninth edition 5000
Digital Twins of Advanced Materials Processing 2000
Weaponeering, Fourth Edition – Two Volume SET 2000
Polymorphism and polytypism in crystals 1000
Signals, Systems, and Signal Processing 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 生物化学 化学工程 物理 计算机科学 复合材料 内科学 催化作用 物理化学 光电子学 电极 冶金 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6022031
求助须知:如何正确求助?哪些是违规求助? 7638908
关于积分的说明 16167722
捐赠科研通 5170058
什么是DOI,文献DOI怎么找? 2766661
邀请新用户注册赠送积分活动 1749784
关于科研通互助平台的介绍 1636740